CRISPR Therapeutics Adds Pablo J. Cagnoni, M.D., to Board of Directors and Names Tony Coles, M.D., Chairman of the Board to Enhance Drug Development and Commercialization Expertise
CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for patients with serious diseases, today announced the appointment of Pablo J. Cagnoni, M.D., to its board of directors. The Company also named current board member, Tony Coles, M.D., as new Chairman of the Board. Dr. Coles succeeds Bradley Bolzon, M.D., Managing Director of Versant Ventures and Founding Chairman since 2013.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160317005477/en/
CRISPR Therapeutics Adds Pablo J. Cagnoni, M.D., to Board of Directors (Photo: Business Wire)
“As Pablo and Tony transition into their new roles, I would like to thank Brad for his leadership and commitment as our Chairman since inception, and am very pleased he will continue guiding the Company as a director,” said Rodger Novak, M.D., Chief Executive Officer of CRISPR Therapeutics. “Pablo is an ideal addition with his deep experience in drug development, translating breakthrough therapeutic approaches into highly innovative drugs for people with cancer and other debilitating diseases. His experience partnering with the medical community to transform treatment paradigms will help expedite the development of novel therapeutics derived from our proprietary technology platform.”
During Dr. Cagnoni’s 25-year career as an oncologist and biopharmaceutical innovator, he has played a key role in the development, approval and/or commercialization of several life-changing medicines, most notably Tarceva®, Afinitor®, and Kyprolis®. Dr. Cagnoni, who has served as Managing Director of MPM Capital since 2015, is currently President and Chief Executive Officer of Tizona Therapeutics and Executive Chairman of Blade Therapeutics. Before this, Dr. Cagnoni served as President of Onyx Pharmaceuticals, a subsidiary of Amgen, where he had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio.
“I am honored and excited to join CRISPR Therapeutics’ Board at a time when its technology has the potential to revolutionize the treatment of some of the world’s most intractable diseases,” said Dr. Cagnoni. “CRISPR Therapeutics has the technology, scientific rigor, resources, world-class team and partners necessary to realize its ambitious mission.”
CRISPR Therapeutics is focused on the discovery and development of potential cures for serious diseases using its proprietary CRISPR-Cas9 gene editing technology. The Company’s multi-disciplinary team of world-class drug developers, clinicians and academics is working on its own proprietary product pipeline and also partnering with some of the world’s leading pharmaceutical and biotechnology companies to translate this technology into breakthrough human therapeutics. The foundational CRISPR-Cas9 patent estate for human therapeutic use was licensed from scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics recently entered into substantial strategic partnerships with Vertex Pharmaceuticals and Bayer.
Prior to his tenure at Onyx/Amgen, Dr. Cagnoni served in executive global development roles at Novartis Oncology, Allos Therapeutics (acquired by Spectrum Pharmaceuticals) and OSI Pharmaceuticals (acquired by Astellas). Dr. Cagnoni earned his medical degree from the University of Buenos Aires School of Medicine, and completed his fellowships in Hematology and Oncology at Mount Sinai Medical Center in New York and in stem cell transplantation at the University of Colorado Health Sciences Center. Before joining industry, he served as Assistant Professor of Medicine at the University of Colorado Bone Marrow Transplant Program.
Dr. Coles joined the Board of Directors of CRISPR Therapeutics in December 2015, and currently serves as Chairman and Chief Executive Officer of Yumanity Therapeutics, a biotechnology company focused on transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Prior to founding Yumanity, Dr. Coles was Chairman and Chief Executive Officer of Onyx Pharmaceuticals. Previously, he held various executive and leadership positions at NPS Pharmaceuticals, Vertex Pharmaceuticals, Bristol-Myers Squibb Company and Merck & Co.
CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com.
W2O Group for CRISPR
Jennifer Paganelli, 347-658-8290
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
FCF: Greenpeace Allegations Unfair and Deceptive26.5.2018 18:02 | Pressemelding
FCF Fishery, Co. President Max Chou today released the following statement regarding recent misleading Greenpeace human rights abuse allegations made against the company: “We realize that as one of the world’s largest marine products integrated supply chain service providers with more than 30 subsidiaries, fishing bases, and shipping agents around the world, we are a prime target for organizations seeking to garner publicity and those not fully aware of the latest development and improvements that are currently taking place in the fishery industry. However, in their efforts to curb egregious human rights abuses, we believe it is unfair and deceptive to lump our company in with those who condone cruelty and neglect of their laborers. “Although we recognize the meaningful work of Greenpeace in exposing and eliminating human trafficking and sustainability abuses, we are equally disappointed that they are implicating FCF in old incidents and cases that have since been in all instances addr
NBC Universal, Havas Group and Endemol Shine Discuss a Future with AI, Blockchain and VR at IBC201825.5.2018 18:20 | Pressemelding
As is fitting for the home of technical invention and innovation, IBC2018 will present a broad range of ambitious and timely elements to engage, inform and inspire content creators and owners from around the world that will visit the RAI, Amsterdam from 13-18 September 2018. The must-attend event includes fresh inspiring conference themes that will focus on innovative new platforms, audience engagement and interaction/immersion, as well as a wide-ranging exhibition that will encompass all the latest technologies from AI and VR to advanced cloud-based workflows. Registration for IBC2018 is now open at: https://ibc.itnint.com/IBC18/Online/RegLogin.aspx “The media landscape is evolving at an unprecedented rate, with new platforms, technologies and even new realities at our disposal that offer greater opportunities for content innovation and audience engagement,” said Michael Crimp, CEO, IBC. “IBC is preparing an outstanding programme of conference sessions, forums and exhibition features
Pavilion of France at the 16th International Architecture Exhibition – La Biennale di Venezia25.5.2018 09:26 | Pressemelding
The concept for Infinite Places , developed by the Encore Heureux team, led by the architects Nicola Delon, Julien Choppin, and Sébastien Eymard, presents places produced by new and inventive processes that generate architectural processes of value. This exhibition project, which considers the territory as a whole, highlights initiatives on the part of civil society and communities that embody a certain free spirit of experimentation and the possibilities opened up by architecture. These projects are expressions of programmatic freedom and generosity, and they live up to the theme of Freespace adopted by the two commissioners of the 16th International Architecture Exhibition – La Biennale di Venezia, the Irish architects Yvonne Farrell and Shelly McNamara. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180525005191/en/ French Pavilion Venice Architectural Biennale, copyright S. Scher Statement of the curators « Through the I
SIA Acquires Card Processing Businesses in Central and Southeastern Europe from First Data25.5.2018 08:30 | Pressemelding
SIA, a European high-tech leader in payment infrastructure and services, and First Data Corporation (NYSE: FDC), a global leader in commerce-enabling technology, have signed an agreement for SIA to acquire First Data’s card processing businesses in parts of Central and Southeastern Europe for €375 million. In 2017, these businesses generated a combined revenue of approximately €100 million for First Data. This acquisition by SIA provides card processing, card production, call center and back-office services, including 13.3 million payment cards, 1.4 billion transactions, in addition to the management of POS terminals and ATMs. These businesses are primarily located in 7 countries: Greece, Croatia, Czech Republic, Hungary, Romania, Serbia and Slovakia. As a result of the transaction, SIA will become a leading player in processing and services in the region. The agreement includes the transfer of about 1,400 First Data employees into SIA. “This acquisition is in line with our strategy to
Westinghouse Accident Tolerant Fuel Development Moves Forward with Cooperation Agreement with ENUSA25.5.2018 06:00 | Pressemelding
Westinghouse Electric Company today announced that it will collaborate in the development of its EnCore® Fuel, the revolutionary accident-tolerant fuel (ATF) design, with ENUSA Industrias Avanzadas (ENUSA) through a Frame Cooperation Agreement (FCA). “This agreement serves to strengthen the technical and commercial relations between ENUSA and Westinghouse as we work to develop leading nuclear fuel technology,” said Torbjörn Norén, European Fuel Group and EMEA Fuel Delivery Director at Westinghouse. “Westinghouse’s work with ENUSA in the Spanish and European Fuel Group markets will help to facilitate agreements with customers to launch EnCore Fuel demonstration programs in their plants.” Under the terms of the agreement, the newly signed FCA establishes the framework that will regulate the different Joint Development Programs (JDPs) to be launched between both companies. The first JDP will evaluate the application of the segmented rod concept and develop models of ATF / EnCore fuel beha
BRIC HOLDING Offers Aimedis – ICO: Germany’s Leading eHealth Platform Goes Public25.5.2018 06:00 | Pressemelding
Since Wednesday, May 16, investors finally have a chance to claim their share of a unique success story, the international market roll-out of Aimedis, by purchasing AIM tokens: AIM tokens are now available with a 20% presale bonus PLUS a 5% early bird-premium only at the Czech investment house BRIC INVEST https://www.bric-holding.com/home_en.html! Aimedis aims to shape the future of healthcare by providing an advanced and fully operational platform, secured by blockchain and supported by AI, that enables patients to take control, secure the exchange of their medical data, access the best healthcare providers, get advice, prescriptions, personal health upgrades and to become part of the health revolution. And we are not talking about the future: The revolutionary Aimedis platform is already deployed as a live working system and is already in use in major hospital groups in Germany! By issuing 300 million AIM tokens at a nominal value of 0,12 USD each, the Aimedis consortium will raise c